NASDAQ:ALKSAlkermes Stock Price, Forecast & News

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALKS stock has increased by 0.7% and is now trading at $16.36. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 11 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Alkermes.

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Alkermes.

Alkermes Plc (NASDAQ:ALKS) issued its quarterly earnings data on Wednesday, April, 29th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.07. The business had revenue of $246.20 million for the quarter, compared to analyst estimates of $230.53 million. Alkermes had a positive return on equity of 4.99% and a negative net margin of 11.63%. The company's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.17) EPS. View Alkermes' earnings history.

12 brokers have issued 12-month price objectives for Alkermes' shares. Their forecasts range from $16.00 to $28.00. On average, they expect Alkermes' stock price to reach $21.17 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price. View analysts' price targets for Alkermes.

Media coverage about ALKS stock has been trending somewhat negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alkermes earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAlkermes.

Alkermes saw a increase in short interest in April. As of April 30th, there was short interest totaling 9,290,000 shares, an increase of 16.6% from the April 15th total of 7,970,000 shares. Based on an average trading volume of 2,020,000 shares, the days-to-cover ratio is presently 4.6 days. Currently, 5.9% of the company's stock are short sold. View Alkermes' Current Options Chain.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Starbucks (SBUX), Alibaba Group (BABA), Walt Disney (DIS), Johnson & Johnson (JNJ) and Pfizer (PFE).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (13.82%), Primecap Management Co. CA (5.67%), BlackRock Inc. (5.55%), Sarissa Capital Management LP (4.53%), Camber Capital Management LP (3.81%) and State Street Corp (2.98%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, Iain Michael Brown, James M Frates, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops. View institutional ownership trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Two Sigma Investments LP, BlackRock Inc., Deutsche Bank AG, Engineers Gate Manager LP, Rafferty Asset Management LLC, Spark Investment Management LLC, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Alkermes company stock in the last year include Iain Michael Brown, Michael J Landine, and Richard F Pops. View insider buying and selling activity for Alkermes.

ALKS stock was purchased by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Maverick Capital Ltd., Camber Capital Management LP, BNP Paribas Arbitrage SA, Invesco Ltd., Atom Investors LP, UBS Group AG, and Krensavage Asset Management LLC. View insider buying and selling activity for Alkermes.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALKS stock can currently be purchased for approximately $16.36.

Alkermes has a market capitalization of $2.60 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

The official website for Alkermes is www.alkermes.com.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]